BioCentury
ARTICLE | Clinical News

M1095: Ph Ib data

February 23, 2017 2:11 AM UTC

A double-blind, German Phase Ib trial in 41 patients with moderate to severe psoriasis showed that 30, 60, 120 and 240 mg doses of subcutaneous M1095 on days 1, 15 and 29 led to PASI 75 response rates...